EU/3/19/2185: Orphan designation for the treatment of marginal zone lymphoma
Table of contents
On 25 July 2019, orphan designation EU/3/19/2185 was granted by the European Commission to Incyte Biosciences Distribution B.V., the Netherlands, for parsaclisib for the treatment of marginal zone lymphoma.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in December 2022 on request of the Sponsor.
Treatment of marginal zone lymphoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Incyte Biosciences Distribution B.V.
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|December 2022||The product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: